CB-10-01 (Transgenic Lymphocyte Immunization)
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IIIB Skin Melanoma
Conditions
Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Trial Timeline
Jun 1, 2007 → Jul 1, 2014
NCT ID
NCT00925314About CB-10-01 (Transgenic Lymphocyte Immunization)
CB-10-01 (Transgenic Lymphocyte Immunization) is a phase 2 stage product being developed by Cosmo for Stage IIIB Skin Melanoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00925314. Target conditions include Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Stage IIIB Skin Melanoma were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00925314 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Stage IIIB Skin Melanoma